Profile picture of Kumar Gogna
Home Doctors A/Prof Kumar Gogna

A/Prof Kumar Gogna

Profile picture of Kumar Gogna

MBBS, DCH, FRCP, FRANZCR

Radiation Oncologist
Call
Enquire
Referrals
Become a Patient Refer a Patient
Greenslopes
07 3099 8400
07 3099 8401
[email protected]

Biography

Special Interests

Languages spoken

Icon Locations

Visiting Locations

Memberships

Publications

Biography

A/Prof N. Kumar Gogna is a senior radiation oncologist at Icon Cancer Centre Greenslopes, Redland and Springfield. He trained as a radiation oncologist at the St Vincent’s Hospital in Sydney and for the last 20 years has been based at the Radiation Oncology Mater Centre in Brisbane.

A/Prof Gogna is one of the founding directors of the Radiation Oncology Queensland (now known as Icon Cancer Centre and part of Icon Group) at the St Andrew’s Hospital in Toowoomba. Over the last nine years A/Prof Gogna and his colleagues have been passionate about taking oncological services to regional and remote areas of the country.

He is vastly experienced and has special interests in the treatment of prostate cancer, bladder cancer, head and neck cancer and lymphoma. He has expertise in seed implant therapy for the management of early stage prostate cancer and was instrumental in setting up the first seed brachytherapy programme in Queensland.

He is actively involved in research activities especially pertaining to the betterment of treatments for urological cancers through the Trans Tasman Radiation Oncology Group (TROG) in Australia. In addition, A/Prof Gogna was previously a member of the executive board of the Faculty of Radiation Oncology with the Royal Australia and New Zealand College of Radiologists (RANZCR).

Currently he is actively involved in the teaching and mentoring of trainee registrars in radiation oncology and is an examiner in pathology for the Part II of the fellowship examination held by the RANZCR. A/Prof Gogna is held in high regard by his colleagues across Australia and New Zealand.

In 2019, A/Prof Gogna was awarded the RANZCR Denise Lonergan Educational Service Award for demonstrating outstanding long-term commitment, participation and leadership in the area of training and education in Radiation Oncology.

Publications

  • Koh, E. S., Gogna, N. K., Minjgee, M., Tsegmed, U., Gonchig, O., Vanchinbazar, E., Erdenetuya, Y., Yap, M. L., Shelton, N., Ochoa, C., Ceylan, A., Lowe, T., Heng, S. M., Scott, A., Oar, A., & Ward, I. (2021). Implementation of 3D conformal radiotherapy technology at the National Cancer Centre Mongolia: A successful Asia-Pacific collaborative initiative. Journal of medical imaging and radiation oncology, 65(4), 454–459.

  • Denham, J., Steigler, A., Joseph, D., Lamb, D., Spry, N., & Duchesne, G. et al. (2015). Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 115(3), 301-307. 

  • Denham, J., Joseph, D., Lamb, D., Spry, N., Duchesne, G., & Matthews, J. et al. (2014). Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. The Lancet Oncology, 15(10), 1076-1089.

  • Woo, H., Begbie, S., Gogna, K., Mainwaring, P., Murphy, D., & Parnis, F. et al. (2014). Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice. Asia-Pacific Journal of Clinical Oncology, 10(3), 228-236. 

  • Denham, J., Nowitz, M., Joseph, D., Duchesne, G., Spry, N., & Lamb, D. et al. (2014). Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced pr. BJU International, n/a-n/a. 

  • Foroudi, F., Pham, D., Rolfo, A., Bressel, M., Tang, C., & Tan, A. et al. (2014). The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. Radiotherapy and Oncology, 111(2), 316-320. 

  • Thiruthaneeswaran, N., Turner, S., Milross, C., & Gogna, K. (2014). Promoting a Research Culture among Junior Radiation Oncologists: Outcomes from the Introduction of the Australian and New Zealand Research Requirement in Training. Clinical Oncology, 26(3), 162-173.

  • Denham, J., Wilcox, C., Joseph, D., Spry, N., Lamb, D., & Tai, K. et al. (2012). Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. The Lancet Oncology, 13(12), 1260-1270. 

  • Gogna, N., Baxi, S., Hickey, B., Baumann, K., Burmeister, E., & Holt, T. (2012). Split-Course, High-Dose Palliative Pelvic Radiotherapy for Locally Progressive Hormone-Refractory Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 83(2), e205-e211. 

  • Hindson, B., Turner, S., Millar, J., Foroudi, F., Gogna, N., & Skala, M. et al. (2012). Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Journal of Medical Imaging and Radiation Oncology, 56(1), 18-30. 

  • Australian Cancer Network Management of Metastatic Prostate Cancer Working Party. (2010). Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate Cancer. Sydney: Cancer Council Australia

  • Morgan, G., Barton, M., Atkinson, C., Millar, J., Gogna, N., & Yeoh, E. (2010). ‘GAP’ in radiotherapy services in Australia and New Zealand in 2009. Journal of Medical Imaging and Radiation Oncology, 54(3), 287-297. 

Special Interests

A/Prof Kumar Gogna accepts referrals for all cancer types, with a special clinical interest in:

  • Genitourinary cancer
  • Head and neck cancer
  • Lymphoma
  • Prostate cancer

Languages spoken

  • English

Visiting Locations

  • Radiation Oncology Mater Centre

Affiliations & Memberships

  • Royal Australian and New Zealand College of Radiologists (RANZCR)
  • Trans Tasman Radiation Oncology Group (TROG)

Publications

  • Koh, E. S., Gogna, N. K., Minjgee, M., Tsegmed, U., Gonchig, O., Vanchinbazar, E., Erdenetuya, Y., Yap, M. L., Shelton, N., Ochoa, C., Ceylan, A., Lowe, T., Heng, S. M., Scott, A., Oar, A., & Ward, I. (2021). Implementation of 3D conformal radiotherapy technology at the National Cancer Centre Mongolia: A successful Asia-Pacific collaborative initiative. Journal of medical imaging and radiation oncology, 65(4), 454–459.

  • Denham, J., Steigler, A., Joseph, D., Lamb, D., Spry, N., & Duchesne, G. et al. (2015). Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 115(3), 301-307. 

  • Denham, J., Joseph, D., Lamb, D., Spry, N., Duchesne, G., & Matthews, J. et al. (2014). Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. The Lancet Oncology, 15(10), 1076-1089.

  • Woo, H., Begbie, S., Gogna, K., Mainwaring, P., Murphy, D., & Parnis, F. et al. (2014). Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice. Asia-Pacific Journal of Clinical Oncology, 10(3), 228-236. 

  • Denham, J., Nowitz, M., Joseph, D., Duchesne, G., Spry, N., & Lamb, D. et al. (2014). Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced pr. BJU International, n/a-n/a. 

  • Foroudi, F., Pham, D., Rolfo, A., Bressel, M., Tang, C., & Tan, A. et al. (2014). The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. Radiotherapy and Oncology, 111(2), 316-320. 

  • Thiruthaneeswaran, N., Turner, S., Milross, C., & Gogna, K. (2014). Promoting a Research Culture among Junior Radiation Oncologists: Outcomes from the Introduction of the Australian and New Zealand Research Requirement in Training. Clinical Oncology, 26(3), 162-173.

  • Denham, J., Wilcox, C., Joseph, D., Spry, N., Lamb, D., & Tai, K. et al. (2012). Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. The Lancet Oncology, 13(12), 1260-1270. 

  • Gogna, N., Baxi, S., Hickey, B., Baumann, K., Burmeister, E., & Holt, T. (2012). Split-Course, High-Dose Palliative Pelvic Radiotherapy for Locally Progressive Hormone-Refractory Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 83(2), e205-e211. 

  • Hindson, B., Turner, S., Millar, J., Foroudi, F., Gogna, N., & Skala, M. et al. (2012). Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. Journal of Medical Imaging and Radiation Oncology, 56(1), 18-30. 

  • Australian Cancer Network Management of Metastatic Prostate Cancer Working Party. (2010). Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate Cancer. Sydney: Cancer Council Australia

  • Morgan, G., Barton, M., Atkinson, C., Millar, J., Gogna, N., & Yeoh, E. (2010). ‘GAP’ in radiotherapy services in Australia and New Zealand in 2009. Journal of Medical Imaging and Radiation Oncology, 54(3), 287-297. 

More information

Become a Patient

Learn more

See all Doctors

Learn more

Your nearest Icon centre

Learn more

Search

Quick links
Contact us
Become a patient